Chu Dijon Bourogne
Dijon, 21000, France
Location status: Recruiting
NCT Number: NCT04819893
The development of the retinal vascular network is completed during the third trimester of pregnancy and and the first 15 days of life of the newborn. This late maturation can be problematic in cases of preterm births and result in immature retinal vascularization, known as retinopathy of prematurity (ROP). Among the various factors influencing retinal vascular development, the tissue content of omega-3 polyunsaturated fatty acids (PUFAs) appears to be a crucial element. In a previous project, OMEGA-ROP, we showed a difference in the blood bioavailability of omega-3 PUFAs in infants born at less than 28 weeks of amenorrhea who develop ROP compared to healthy newborns with no retinopathy. This study also showed that mothers experienced variations in the blood levels of omega-3 PUFAs that were contrary to the types of variations observed in their children. This suggests a sequestration of omega-3 PUFAs in the mothers of children who will develop ROP. This new project aims to better understand the underlying molecular mechanisms by studying the expression levels of placental fatty acid receptors in relation to the development of ROP in newborns.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Dijon, 21000, France
Location status: Recruiting
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
5 mL sample of venous blood on arrival at the maternity ward in accordance with standard protocols
0.5mL sample from the umbilical cord after childbirth standard protocols
Sampling of 3 cotyledons by cutting across the thickness of the placenta
Newborn, Maternal and Premature Retinopathy Screening Data Collection
Time frame: 16 weeks maximum after birth
Contact information is provided by the study sponsor or research team.
Centre Hospitalier Universitaire Dijon
Other
Acronym: OMEGAROP 2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06420531
Female Urogenital Diseases and Pregnancy Complications, Obstetric Labor Complications
Birmingham, Alabama, United States
View Trial DetailsNCT05340465
Anemia, Anemia, Hypochromic
Seattle, Washington, United States
View Trial DetailsNCT06965530
Birth Outcome, Adverse, Female Urogenital Diseases and Pregnancy Complications
Cleveland, Ohio, United States
View Trial DetailsNCT06536296
Female Urogenital Diseases and Pregnancy Complications, Infant Development
New Haven, Connecticut, United States
View Trial Details